Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.67 |
| ▸ | TK1 | P04183 | 5/20 | 0.60 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2455603 | 1.00 | DHFR (0.67) | DHFRTK1NT5MALBPKM | |
| SCHEMBL31084252 | 1.00 | DHFR (0.67) | DHFRTK1NT5MALBPKM | |
| SCHEMBL12303789 | 1.00 | DHFR (0.67) | DHFRTK1NT5MALBPKM | |
| SCHEMBL22992469 | 0.85 | DHFR (0.60) | DHFRTK1NT5MALBPKM | |
| SCHEMBL8962393 | 0.85 | DHFR (0.60) | DHFRTK1NT5MALBPKM | |
| SCHEMBL9216396 | 0.83 | NT5M (0.59) | DHFRTK1NT5M | |
| SCHEMBL13847480 | 0.83 | NT5M (0.59) | DHFRTK1NT5M | |
| SCHEMBL13883599 | 0.81 | TK1 (0.52) | DHFRTK1ALBPKMLMNA | |
| SCHEMBL14590480 | 0.81 | TK1 (0.59) | DHFRTK1ALBPKMLMNA | |
| SCHEMBL18837842 | 0.81 | TK1 (0.66) | TK1ALBPKMLMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4114406-A1 | SYNTHESIS AND IMPROVEMENT OF A NUCLEOSIDE ANALOGUE AS AN ANTI-CANCER AND ANTI-VIRAL DRUG | Gaziantep Universitesi Rektörlügu (TR) | 2023-01-11 | — | — | EP | claimed |
| EP-4114406-A1 | SYNTHESIS AND IMPROVEMENT OF A NUCLEOSIDE ANALOGUE AS AN ANTI-CANCER AND ANTI-VIRAL DRUG | Gaziantep Universitesi Rektörlügu (TR) | 2023-01-11 | — | — | EP | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-2752422-B1 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-8859756-B2 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2552931-B1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | GILEAD PHARMASSET LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752422-A1 | Stereoselective synthesis of phosphorus containing actives | Gilead Pharmasset LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-5212294-A | Production of 2',3'-dideoxy-2',3'-didehydronucleosides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-05-18 | — | — | US | disclosed |
| US-5130421-A | Production of 2',3'-dideoxy-2',3'-didehydronucleosides | BRISTOL-MYERS COMPANY (US) | 1992-07-14 | — | — | US | disclosed |
| US-4904770-A | Production of 2',3'-dideoxy-2',3'-didehydronucleosides | BRISTOL-MYERS COMPANY (US) | 1990-02-27 | — | — | US | disclosed |
| EP-0334368-A2 | Production of 2',3'-dideoxy-2',3'-Didehydronucleosides | Bristol-Myers Squibb Company (US) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | DHFR 1717/4885TK1 512/4885NT5M 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.